Novel diagnostic and treatment strategies for poorly cohesive gastric cancer
-
By
-
Margherita Muratore
-
Francesco Giulio Sullo
-
Alessandro Bittoni
-
Lina Cardisciani
-
Martina Valgiusti
-
Giulia Bartolini
-
Luca Esposito
-
Chiara Molinari
-
Richard Camara
-
Alessandro Passardi
-
August 25, 2026
Clinical Scorecard: Novel diagnostic and treatment strategies for poorly cohesive gastric cancer
At a Glance
| Category | Detail |
|---|
| Condition | Poorly cohesive gastric cancer (PCGC) |
| Key Mechanisms | Diffuse growth, substantial intratumoral heterogeneity, and poor prognosis. |
| Target Population | Patients with poorly cohesive gastric cancer, including signet-ring cell carcinoma. |
| Care Setting | Oncology and pathology settings focusing on gastric cancer management. |
Key Highlights
- PCGC is characterized by discohesive malignant cells and lacks gland formation.
- Molecular profiling has identified actionable biomarkers like HER2, PD-L1, and Claudin 18.2.
- Current treatments primarily involve systemic chemotherapy, with limited survival benefits.
- Emerging therapies include targeted agents and immunotherapeutics.
- Advancements in digital pathology and multi-omics may enhance diagnostic accuracy.
Guideline-Based Recommendations
Diagnosis
- Utilize molecular profiling to identify actionable biomarkers.
Management
- Consider targeted therapies based on identified biomarkers.
Monitoring & Follow-up
- Regular assessment of biomarker expression to guide treatment adjustments.
Risks
- Poor prognosis associated with delayed diagnosis and treatment.
Patient & Prescribing Data
Patients diagnosed with poorly cohesive gastric cancer.
Therapeutic decisions should be informed by molecular characteristics and histological subtype.
Clinical Best Practices
- Integrate histomorphological and molecular tumor characteristics for personalized treatment.
- Employ advanced diagnostic technologies to improve prognostic stratification.
Related Resources & Content
